Search

Your search keyword '"Zhang, Qianfeng"' showing total 2 results
Start Over Author "Zhang, Qianfeng" Topic dendrimers
2 results on '"Zhang, Qianfeng"'

1. Dendron-Functionalized Polyglutamate-Pyropheophorbide-a Conjugates as Nanomedicines for Breast Cancer Photodynamic Therapy.

Author

Wang W, Zhang Q, Li Z, Zhang J, Pan D, Wang B, Zhu H, Zhang H, Gu Z, and Luo K

Subjects
Animals, Cell Line, Tumor, Female, Humans, Nanomedicine, Photosensitizing Agents pharmacology, Photosensitizing Agents therapeutic use, Polyglutamic Acid, Breast Neoplasms drug therapy, Dendrimers, Photochemotherapy
Abstract

Photodynamic therapy (PDT) has shown its promise in the treatment of cancer. Herein, a dendron-functionalized polyglutamic acid (PGA) polymer (PG-L8G-Ppa-Dendron, PGPD) is synthesized and it is conjugated with pyropheophorbide-a (Ppa) for the first time to treat triple negative breast cancer (TNBC), whereas a linear polyglutamate-Ppa conjugate (PGP) is synthesized as a control. Compared to the linear counterpart, the glycosylated polymer-based PGPD with a dendritic structure has excellent solubility and it self-assembles to form uniform-sized nanoparticles. PGPD displays a highly effective PDT effect in the animal model, evidenced with effective induction of reactive oxygen species (ROS) production and cell apoptosis. This may be due to an enhanced efficiency in delivery and accumulation of Ppa by this glycosylated dendritic polymer at tumor sites. Therefore, PGPD can be a highly effective and biosafe nanoagent for PDT of TNBC., (© 2021 Wiley-VCH GmbH.)

Published
2021
Full Text
View/download PDF

2. Dendron-polymer hybrid mediated anticancer drug delivery for suppression of mammary cancer.

Author

Pan, Dayi, Zheng, Xiuli, Chen, Miao, Zhang, Qianfeng, Li, Zhiqian, Duan, Zhenyu, Gong, Qiyong, Gu, Zhongwei, Zhang, Hu, and Luo, Kui

Subjects
ANTINEOPLASTIC agents, DOXORUBICIN, DRUG delivery systems, BLOOD circulation, TUMOR growth, TREATMENT effectiveness
Abstract

Dendron-polymer-based nanoscale and stimuli-responsive drug delivery systems have shown great promise in tumor-targeting accumulation without significant toxicity. Here we report a dendronized polymer-doxorubicin (DOX) hybrid (DPDH) with an improved in vivo drug delivery efficiency for cancer therapy compared with a linear polymer-DOX conjugate (LPDC). The in vitro drug release profile of DOX indicates that DPDH displays pH-responsive drug release due to cleavage of hydrazone bonds since a greater amount of DOX is released at pH 5.2 at a faster rate than at pH 7.4. DPDH efficiently enters 4T1 cells and releases DOX to induce cytotoxicity and apoptosis. Owing to the dendronzied structure, DPDH has a significantly longer blood circulation time than LPDC. DPDH substantially enhances the therapeutic efficacy to suppress tumor growth in a 4T1 mammary cancer model than LPDC as well as free drug, evidenced from tumor growth inhibition, TUNEL assessment and histological analysis. Biosafety of DPDH is also confirmed from hemolysis, body weight shifts during treatment and pathological analysis. This study demonstrates the use of dendronized polymer-DOX hybrids for specific drug molecules is a promising approach for drug delivery. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results